NEW ORLEANS, May 21 /PRNewswire-FirstCall/ — Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical
company, today announced new findings on once-daily INTUNIV™ (guanfacine)
Extended Release Tablets, the first selective alpha-2A agonist
approved for the treatment of Attention Deficit Hyperactivity
Disorder (ADHD), at a
major psychiatric meeting.  The primary objective of this
study was to evaluate the efficacy of INTUNIV, dosed either in the
morning or evening compared with placebo, when co-administered with
stimulant medications used to treat ADHD in children and
adolescents ages 6 to 17 with ADHD and
suboptimal response to stimulant alone.  The study met its
primary end point, which was the change from baseline to end point
in the ADHD Rating Scale-IV (ADHD RS-IV) total score.

“A considerable number of pediatric pat

‘/>”/>

SOURCE